Capricor Therapeutics (CAPR) Earnings Date & Reports

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CAPR is expected to report earnings to fall 39.00% to -32 cents per share on August 07

Capricor Therapeutics CAPR Stock Earnings Reports

Q2'25

Est.

$-0.32

Q1'25

Missed

by $0.21

Q4'24

Beat

by $0.01

Q3'24

Missed

by $0.02

Q2'24

Beat

by $0.01

The last earnings report on May 13 showed earnings per share of -52 cents, missing the estimate of -31 cents. With 2.71M shares outstanding, the current market capitalization sits at 333.44M.

View a ticker or compare two or three

Compare

CAPR